IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MEREGALLI, MIRELLA ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.310
NA - Nord America 6.823
AS - Asia 6.361
SA - Sud America 672
AF - Africa 164
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 14
Totale 21.370
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.543
GB - Regno Unito 2.177
CN - Cina 2.051
SG - Singapore 1.972
IT - Italia 962
DE - Germania 940
SE - Svezia 878
RU - Federazione Russa 633
HK - Hong Kong 593
BR - Brasile 488
IN - India 360
VN - Vietnam 352
FR - Francia 341
NL - Olanda 326
UA - Ucraina 290
TR - Turchia 257
CA - Canada 200
BD - Bangladesh 193
IE - Irlanda 191
KR - Corea 190
FI - Finlandia 188
EU - Europa 148
PL - Polonia 93
JP - Giappone 81
CI - Costa d'Avorio 76
ID - Indonesia 74
CO - Colombia 72
GR - Grecia 60
BE - Belgio 49
MX - Messico 43
AR - Argentina 42
ES - Italia 36
IQ - Iraq 36
DK - Danimarca 28
RO - Romania 25
CH - Svizzera 23
PH - Filippine 22
UZ - Uzbekistan 22
AU - Australia 19
IR - Iran 19
MA - Marocco 19
PK - Pakistan 19
VE - Venezuela 17
ZA - Sudafrica 17
EC - Ecuador 16
TW - Taiwan 16
IL - Israele 15
CL - Cile 13
AT - Austria 12
AE - Emirati Arabi Uniti 11
MY - Malesia 11
SA - Arabia Saudita 11
PY - Paraguay 10
JM - Giamaica 9
LB - Libano 9
PE - Perù 9
TH - Thailandia 9
CZ - Repubblica Ceca 8
EG - Egitto 7
KE - Kenya 7
SK - Slovacchia (Repubblica Slovacca) 7
AZ - Azerbaigian 6
NP - Nepal 6
NZ - Nuova Zelanda 6
TN - Tunisia 6
AL - Albania 5
JO - Giordania 5
KZ - Kazakistan 5
LT - Lituania 5
SC - Seychelles 5
TT - Trinidad e Tobago 5
AO - Angola 4
BG - Bulgaria 4
BH - Bahrain 4
CR - Costa Rica 4
DZ - Algeria 4
ET - Etiopia 4
NO - Norvegia 4
PA - Panama 4
SI - Slovenia 4
XK - ???statistics.table.value.countryCode.XK??? 4
CG - Congo 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KG - Kirghizistan 3
LV - Lettonia 3
PS - Palestinian Territory 3
RS - Serbia 3
UY - Uruguay 3
BO - Bolivia 2
CY - Cipro 2
HR - Croazia 2
LU - Lussemburgo 2
LY - Libia 2
MD - Moldavia 2
NG - Nigeria 2
PT - Portogallo 2
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 21.482
Salva come PNG Salva come JPEG
Città #
Southend 1.974
Singapore 1.187
Ashburn 673
Chandler 564
Hong Kong 563
Beijing 463
San Jose 402
Seattle 370
Milan 321
Princeton 271
Wilmington 250
Dallas 249
Jacksonville 205
Council Bluffs 188
Dublin 188
Mountain View 168
Frankfurt am Main 166
Fairfield 161
Santa Clara 157
Los Angeles 156
Ann Arbor 152
Nanjing 141
Redmond 141
Bengaluru 135
Toronto 124
Moscow 123
Woodbridge 117
Munich 116
Lauterbourg 110
Boardman 104
Ho Chi Minh City 103
Phoenix 95
New York 94
Sakarya 91
Des Moines 90
Buffalo 86
Hanoi 83
Dearborn 81
Shanghai 79
Warsaw 78
Abidjan 76
Medford 74
Helsinki 68
Guangzhou 63
Serra 63
Andover 62
Houston 62
Bogotá 59
São Paulo 59
Hanover 57
Cambridge 55
Athens 54
Shenyang 53
Tokyo 53
Sunnyvale 51
Tianjin 51
Jinan 46
Changsha 44
Columbus 44
Rome 42
Somerville 42
Brussels 40
Chicago 37
Redwood City 37
Jakarta 36
Nanchang 35
Hefei 34
Cangzhou 32
Fuzhou 32
Hebei 32
San Diego 32
Eitensheim 31
Berlin 30
London 29
Hangzhou 28
Bitonto 27
Mumbai 27
The Dalles 27
Roxbury 24
Grafing 22
Hamburg 22
Nuremberg 22
Odernheim 21
Quanzhou 21
Zhengzhou 20
Ottawa 19
Da Nang 18
Orem 18
Wuhan 18
Seoul 17
Amsterdam 16
Montreal 15
Falls Church 14
Kunming 14
Shenzhen 14
Turin 14
Auburn Hills 13
Boston 13
Falkenstein 13
Haikou 13
Totale 12.924
Salva come PNG Salva come JPEG
Nome #
Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy 375
Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle 359
CD133+ cells isolated from various sources and their role in future clinical perspective 346
Modificazione genica di cellule staminali distrofiche allo scopo di trapianto autologo nella distrofia muscolare di Duchenne 329
Impaired Angiogenic Potential of Human Placental Mesenchymal Stromal Cells in Intrauterine Growth Restriction 310
Induction of neurotrophin expression via human adult mesenchymal stem cells : implication for cell therapy in neurodegenerative diseases 298
Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle 281
T and b lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse 278
Autologous intramuscular transplantation of engineered satellite cells induces exosomemediated systemic expression of Fukutin-Related Protein and rescues disease phenotype in a murine model of Limb-Girdle Muscular Dystrophy Type 2I. 274
Exome sequencing identifies variants in two genes encoding the LIM-proteins NRAP and FHL1 in an Italian patient with BAG3 myofibrillar myopathy 264
Skin-derived stem cells transplanted into resorable guides provide functional nerve regeneration after sciatic nerve resection 254
Correlation of circulanting CD133+ progenitor subclasses with a Mild phenotype in Duchenne Muscular dystrophy patients 247
Stem cells and muscular dystrophies 246
Characterization of muscle-specific expression of miRNAs in duchenne muscular dystrophy 245
Abundance of circulating progenitors with myo-endothelial potential correlates with a mild phenotype in patients affected by Duchenne muscular dystrophy 235
Morphological modifications of resected sciatic nerve after autologous transplantation of skin-derived stem cells into resorable guides. 234
High Mobility group protein 3 (Hmgb3) is regulated by microRNA-206 during muscle regeneration 234
Autologous transplantation of skin-derived stem cells and functional nerve regeneration after a peripheral nerve lesion 233
Combining Stem Cell and Exon Skipping Approach to Treat Muscular Dystrophies 233
VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation 229
Advancements in stem cells treatment of skeletal muscle wasting 221
Impact of Muscular Dystrophy on the Regenerative Properties of interstitial Muscle Cells 221
CD20-related signaling pathway is differently activated in normal and dystrophic circulating CD133+ stem cells 220
Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model 219
Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect 219
Isolation and characterization of cells coexpressing endothelial progenitors and parathyroid specific genes from human adult normal and tumoral parathyroids 215
Abundance of circulating progenitors with myo-endothelial potential correlates with a mild phenotype in patients affected by Duchenne muscular dystrophy 208
Development of a new technique for muscle tissues-stem cells co-colture 205
Human circulating AC133+ stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle 205
Human fetal CD133+ skeletal muscle cells expressing pericyte merkers generate muscle and endothelial cells and repair dystrophic muscle tissues. 199
Combining gene and stem cell therapy in the treatment of disferlinopaties 199
Difference in myogenic properties of the blood-derived AC133+ stem cells subpopulation isolated from normal and dystrophic tissues 197
Role of skin derived stem cells in peripheral nerve regeneration 196
Perspectives of Stem Cell Therapy in Duchenne Muscular Dystrophy 196
Myogenic potential of human circulating AC133+ stem cells in murine dystrophic skeletal muscle 195
Cellule staminali e rigenerazione muscolare 195
Exome sequencing identifies variants in two genes encoding the lim-proteins n-rap and fhl1 in a bag3 myofibrillar myopathy 194
MicroRNA-206 is upregulated in an animal model of Duchenne Muscular Distrophy 193
Expression of parathyroid-specific genes in vascular endothelial progenitors of normal and tumoral parathyroid glands 192
Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection 191
Cell Therapy of Muscular Dystrophy with Engineered CD133+ Cells 191
Blood-derived CD133+ stem cells from normal and dystrophic tissues: a comparative study with clinical applications 190
Cell Theraphy of Muscolar Dystrophy with Engineered CD133+Cell 190
In Vivo Tracking of Stem cell by Nanotechnologies : Future Prospect for Mouse to Human Translation 190
Combining multiple therapeutic strategies for Friedreich’s ataxia (FRDA): antioxidant metallic nanoclusters as coadjuvants for gene and stem cell therapy 189
In vitro and In Vivo mesenchymal stem cells neurothrophin production but limited neuronal differantiation 188
Full-length dysferlin expression driven by engineered human dystrophic blood-derived CD133+ stem cells 187
MicroRNA-206 is upregulated in an animal model of Duchenne Muscular Distrophy. 186
Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model 186
Development of new technologies Including myogenic differentiation of human circulating CD133+cells 184
Ex vivo expansion of human circulating CD133+ progenitors cells: promising tool for cell-based therapeutic approaches in muscular dystrophy. 182
Combining Gene and Stem Cell therapy in the Treatment of Dysferlinophaties 182
Differential Activativation of CD20-Related Signalling Pathway Results in Distinct Differentiation Behaviour of Normal and DMD Circulating CD133+ Stem Cells 181
Exome sequencing identifies mutations in two genes encoding the LIM-proteins N-RAP and FHL1 in a BAG3 myofibrillar myopathy 181
The myomiR-206 partecipate to muscle-regeneration by sculpting the chromatin through the down.regulation of the non-histone chromatin-associated protein High Mobility group protein 3 (Hmgb3) 178
Preclinical experience and perspectives of a clinical trial using cD133 stem cells 178
Combining stem cells and exon skipping strategy to treat muscular dystrophy 177
The role of stem cells in muscular dystrophy 176
The involvement of microRNAs in neurodegenerative diseases 176
Cell Based Therapy for Duchenne Muscular Dystrophy 175
Muscle-specific microRNAs (mirnas) in Duchenne Muscular Distrophy (DMD). 175
Ex vivo expansion of human circulanting CD133+promising tool for cell-based therapeutic approaches in muscular dystrophy 173
Muscular dystrophies therapies by engineered stem cells 173
Hmgb3 Is Regulated by MicroRNA-206 during Muscle Regeneration 173
Exon-skipping of dysferlin in CD133+ stem cells isolated from normal and patient affected with dysferlinopathies. 172
Ex vivo expansion of peripheral blood CD133+ progenitors cells: promising tool for cell-based therapeutic approaches in muscular dystrophy. 170
Development of New technologies Inducing Myogenic Differentiation of Human Circulating CD133+ Cells 169
Proliferation and Clonal Analysis of Muscle Derived CD133+ Stem Cell Subpopulations Define a Depletion of Mesenchymal Population in DMD Patients 169
Muscle-specific microRNAs (mirnas) in Duchenne Muscular Distrophy (DMD). 168
Stem Cell Therapies to Treat Muscular Dystrophy : Progress to Date 168
Proliferation and clonal characterization of human muscle derived CD133+ positive stem cells define an intrinsic heterogeneity 168
Absence of T and B lymphocytes enhances skeletal muscle regeneration and ameliorates dystrophic pathology in dysferlin deficient animal model 168
Autologous transplantation of engineered muscle-derived CD133+ stem cells 167
Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy 167
Myogenic differentiation potential of CD133+ stem cells isolated from various sources 165
Predicted miRNAs in murine dystrophin gene 164
Combining Stem Cells and Exon-Skipping and Approch to Treat Muscular Dystrophies 163
Predicted miRNAs in murine dystrophin gene 163
Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs 163
Duchenne muscular dystrophy caused by a frame-shift mutation in the acceptor splice site of intron 26 163
In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled CD133+ stem cell tropism to dystrophic muscle tissues using micro-CT imaging 162
Adaptive immune response impairs the efficacy of autologous transplantation of engineered stem cells in dystrophic dogs 162
Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-Related Protein and rescues disease phenotype in a murine model of Limb-Girdle Muscular Dystrophy Type 2I 162
Differential Activation of CD20-related Signaling Pathways Results in distinct differentiation behaviour of normal and DMD circulating CD133+ Stem Cells 161
CD133+ Cells for the Treatment of Degenerative Diseases : update and perspectives 161
Human Fetal CD133+ Muscle Cells Expressing Perycite Markers Repair Dystrophic Muscle Tissue. 156
MiRNAs dysregulation of Single Muscle Fibers in Duchenne Muscular Dystrophy 155
Mesenchymal Stem Cells as Muscle Reservoir 155
Rescue of human dystrophin after transplantation of exon-skipping-engineered DMD stem cells in a dystrophic animal model 154
Abundance of Circulating Progenitors with Myo-Endothelial Potential Correlates with a Mild Phenotype in Patients Affected by Duchnne Muscular Dystrophy 154
Effective high-throughput isolation of enriched platelets and circulating pro-angiogenic cells to accelerate skin-wound healing 154
Metformin rescues muscle function in {BAG}3 myofibrillar myopathy models 153
Réhabilitation de la dystrophine humaine dans le modèle scid/mdx après greffe de cellules souches de patients DMD corrigées par saut d’exon 152
Perturbation of calcium handling in CD133+ stem cells isolated from DMD blood 152
Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect 148
Cell replacement therapy in neuromuscular and neurodegenerative diseases 145
Thermoresponsive material for muscle cell sheet engineering 144
Stem cell therapy of muscular dystrophies using exon skipping approach in GRMD dogs 144
Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice 142
Improvement of endurance of DMD animal model using natural polyphenols 140
Totale 19.668
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021446 0 0 0 0 0 0 0 0 0 0 368 78
2021/20221.512 126 69 32 87 69 114 112 46 235 104 166 352
2022/20232.160 327 244 196 253 237 370 32 143 252 19 60 27
2023/20241.127 38 86 50 90 357 61 49 50 17 59 104 166
2024/20253.140 113 259 62 382 248 101 190 321 133 315 254 762
2025/20265.783 683 367 551 471 593 426 799 324 601 483 485 0
Totale 22.465